Aurora Cannabis Inc. (ACB) shares soared 46% in the last trading session to close at $9.23. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 46.6% gain over the past four weeks.The sharp upsurge in Aurora's shares can be attributed to the DEA's reported decision to reclassify marijuana from Schedule I (reserved for drugs with a high potential for abuse) to Schedule III (reserved for drugs with a moderate to low potential for physi ...

The US is planning to reclassify cannabis as a less dangerous drug in an historic shift that could have a significant impact across the country.The Drug Enforcement Administration's (DEA) proposal would recognise the drug's medical properties and acknowledge it has less potential for abuse than other dangerous substances. However the proposal, which still must be reviewed by the White House, would not legalise cannabis outright for recreational use.Marijuana is currently classified in the US as a "schedule ...

Cannabis stocks soared nearly across the board this afternoon on news that President Joe Biden’s administration is moving to reschedule marijuana as a Schedule III substance, a less severe designation than its prior Schedule I classification. Indeed, acting on a review from the Department of Health and Human Substances, the U.S. Drug Enforcement Administration (DEA) and U.S. Justice Department may recategorize cannabis as early as this week. A move to Schedule III would yield major benefits to both the lega ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

The new dried flowers, including Black Jelly, Chemango Kush, and Moon Berry, are proprietary cultivars cultivated exclusively by Aurora. Vespera, a previously existing proprietary cultivar, is also set for relaunch under the Aurora brand. These products mark a significant step forward for MedReleaf Australia as they continue to expand their offerings under the Aurora brand.  The dried flower products are available now in four 10g formats including: Aurora Moon Berry T9/C13 Balanced Aurora Black Jelly T28 ...

Ahead of the Curve: Leading Canadian Cannabis Stocks for Early 2024The global cannabis industry and top marijuana stocks are poised for significant growth, driven by increasing legalization and medical use. Furthermore, experts predict a compound annual growth rate of over 20% for the next decade. Consequently, this expansion benefits top Canadian companies such as Canopy Growth, Aurora Cannabis, and Aphria. These firms lead the market in innovation and distribution. Therefore, investors should closely moni ...

Cannabis stocks may be some of the most controversial investment ideas. But they are also turning out to be one of the most profitable. For example, over the last few weeks, related stocks like Canopy Growth (NASDAQ:CGC) ran from a low of $2.75 to a high of $11.57. And while CGC recently pulled back to $6, it’s just starting to pivot higher again.All thanks to growing U.S. support for legalization — with 88% of the public believing it should be legal for medicinal and recreational use. Florida may soon lega ...

股价表现 - Aurora Cannabis Inc. (ACB)最新收盘价为$6.46，较前一个交易日下跌了1.15%[1] - 近一个月来，该公司股价上涨了70.18%[2] 财务预期 - 投资者将密切关注Aurora Cannabis Inc.即将发布的财报，预计每股收益为-0.18美元，同比增长88%[3] 分析师观点 - 分析师对公司的业务健康和盈利能力持乐观态度[4]

Leading Canadian Cannabis Companies to ConsiderAs we move into mid-April 2024, Canadian marijuana stocks are capturing the attention of investors, given the ongoing developments and shifts in the global cannabis market. Stocks like Tilray, Canopy Growth, and Aurora Cannabis are notable for their robust international operations and diverse product lines. Tilray, for example, has expanded its presence in the U.S. through acquisitions like MedMan, positioning it well to capitalize on potential market expansion ...

If even Tilray can't make money from marijuana, what hope does any company have?Tuesday is turning into a lousy day to own marijuana stocks, as bad news from cannabis company Tilray Brands (TLRY -19.30%) is taking a toll on pretty much every other marijuana stock out there. Tilray reported a miss on sales this morning and a $0.12 per-share net loss.Shares of Cronos Group (CRON -1.86%), Canopy Growth (CGC -8.74%), and Aurora Cannabis (ACB -8.55%) are all suffering as a result, down 3.5%, 7.8%, and 8.5%, resp ...